The Australasian Myeloma Research Consortium (AMaRC) in collaboration with theAustralasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related DiseasesRegistry (MRDR) is conducting a phase II study to investigate the optimal usage oflenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma patientsbased on a frailty score (frailty is characterised by a decline in body functions). If...Continue Reading
The New Zealand Myeloma Interest Group is comprised of representative haematologists from District Health Boards around the country with a special interest and expertise in MM. We reviewed the currently available evidence, including randomised controlled trials, retrospective data and conference abstracts, and interpreted these in the context of treatment options available in New Zealand to...Continue Reading
Myeloma experts convened in person and online for the 2022 Multiple Myeloma Queenstown Summit, hosted by Myeloma New Zealand. This year’s meeting included presentations from local and international experts, including the Chief Medical Officer of the International Myeloma Foundation, Professor Joseph Mikhael, Assistant Professor Jonathan Keats from Arizona, and Professor Simon Harrison and Dr Simon...Continue Reading
Myeloma New Zealand has started a campaign to press Pharmac into funding a treatment that has been standard-of-care throughout the Organisation for Economic Co-operation and Development (OECD) for more than five years. Myeloma NZ trustee Nichola Oakenfull has been interviewed for the article, well done Nichola! Here is the RNZ article: https://www.rnz.co.nz/news/national/474629/blood-cancer-patient-charity-campaigns-for-pharmac-to-fund-medicineContinue Reading
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You know it’s a good product. It works. You need it. And you’ve got the money to buy it. So how long will it take? What if I said...Continue Reading
In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again in 2022, the Summit brings together medical professionals involved with Myeloma in NZ to share and to learn from one another and from the international speakers who join the meeting. This year...Continue Reading
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review Panel has been sitting with Health Minister Andrew Little since February, with no reason offered for why it has not been released, says Myeloma NZ Chief Executive Dr Ken Romeril. “Given the damning...Continue Reading
Congratulations on your very well-deserved appointment to The New Zealand Order of Merit for your services to Haematology! Dr Ken Romeril is a consultant physician/haematologist. Dr Ken Romeril (Ken) founded the charitable trust Myeloma New Zealand, of which he has been CEO since 2016, continuing in this role following retirement from clinical practice. He is the...Continue Reading
